Singapore: NUS-Agilent Hub New Translational R&D Hub to Boost Clinical Diagnostics
The National University of Singapore (NUS), Agilent Technologies, and the National University Hospital (NUH), have established Singapore’s first integrated translational R&D hub. It's purpose is to leverage biochemical innovation and research data analytics for developing new methods of translating clinical research into clinical diagnostics.
Singapore — The NUS-Agilent Hub for Translation & Capture was officially launched by Associate Professor Benjamin Ong, Director of Medical Services of the Ministry of Health, at the opening ceremony held at the National University of Singapore (NUS). The research hub, which comprises laboratories located at the University and the National University Hospital, provides 1000 m2 of research space to facilitate multidisciplinary collaborations among scientists, clinicians, and industry partners to translate biochemical research into clinical applications. Through research in areas such as lipidomics and synthetic biology, and supported by data analytics, the University and its partner hope to develop innovative ways that enhance the accuracy of clinical diagnostics based on data obtained from patients’ blood samples. The initial research focus areas are cardiovascular disease and diabetes, which account for 30 % of all deaths in Singapore in 2017.
The “hub and satellite model” is to allow research to be conducted centrally, Singapore-based, but shared broadly, both locally, regionally as well as globally through key partnerships and alliances supported by NUS and Agilent.